A Leader in the Discovery and Development of First- and Best-in-class Small Molecule Cancer Therapies

Ascentage Pharma is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs. For more than two decades, our founders and team have leveraged their deep expertise to develop our proprietary drug discovery platform to pursue particularly challenging targets. We are the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators that restore programmed cell death. Our clinical candidates include novel Bcl-2 and Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). We have eleven completed or ongoing international registrational trials, including two that are FDA-regulated.

Ascentage is bringing innovative therapies to patients across the world for cancers and other diseases, using expertise in compounds that affect programmed cell death.

HQP1351

Olverembatinib

Treatment resistant cancers

BCR-ABL/KIT KINASE

APG-2575

Lisaftoclax

Leukemias & additional blood cancers

BCL-2

APG-1252 diagram

APG-1252

Pelcitoclax

Solid tumors & blood cancers

BCL-2/XL

APG-115

APG-115

Alrizomadlin

Solid Tumors & Blood Cancers

MDM2-P53

Partnering with Ascentage

Ascentage actively seeks co-development and co-promotion partnerships as part of a comprehensive strategy to accelerate the development of our lead assets in the global marketplace. We are continually looking to identify partners with portfolios that are complementary to the specific mechanisms of action of our therapeutic candidates.

Learn More